Short Term Trading Week Starting: 21 May, page-72

Here's a quick few notes from last research (last month).

Latest is the interim results being presented in London on the 25 th May, and then a public webinar on the 29th and 30th May.

Trials:
Cancer: lung, breast, head and nack, ovarian, Melanona
+ 2 results due 'mid 2018' - Phase 1 TACTI (interim results 25th); AIPAC
+ lead products IMP321, IMP761
+ new trial H2 2018 - TACTI 002; FDA approval H1 2018.
+ Chinese parrtners EOL - H1 2018 EFTI trial results
+ Japanese partners CYTLIMIC - phase 1 begun

Will make all that more cohesive later.